摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl (3R,4R)-4-fluoro-3-hydroxypiperidine-1-carboxylate

中文名称
——
中文别名
——
英文名称
tert-butyl (3R,4R)-4-fluoro-3-hydroxypiperidine-1-carboxylate
英文别名
(3R,4R)-1-Boc-4-fluoro-3-piperidinol
tert-butyl (3R,4R)-4-fluoro-3-hydroxypiperidine-1-carboxylate化学式
CAS
——
化学式
C10H18FNO3
mdl
——
分子量
219.256
InChiKey
FZAKOAFETOZBLC-HTQZYQBOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.9
  • 拓扑面积:
    49.8
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    tert-butyl (3R,4R)-4-fluoro-3-hydroxypiperidine-1-carboxylate盐酸 作用下, 以 二氯甲烷 为溶剂, 反应 2.0h, 以100%的产率得到(3R,4R)-4-fluoropiperidin-3-ol
    参考文献:
    名称:
    HPK1 ANTAGONISTS AND USES THEREOF
    摘要:
    本发明提供了化合物、其组合物以及使用这些化合物用于抑制HPK1和治疗HPK1介导的疾病的方法。
    公开号:
    US20210078996A1
  • 作为产物:
    描述:
    参考文献:
    名称:
    [EN] 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND MEDICAL USES THEREOF
    [FR] DÉRIVÉS DE 3-(1-OXOISOINDOLIN-2-YL)PIPÉRIDINE-2,6-DIONE ET LEURS UTILISATIONS MÉDICALES
    摘要:
    该申请涉及式(I)的化合物、包含它们的制药组合物以及它们在降低广泛间隔锌指结构基序(WIZ)表达水平、诱导胎儿血红蛋白(HbF)表达和治疗遗传性血液疾病(如血红蛋白病,如镰状细胞贫血和β-地中海贫血)方面的用途。
    公开号:
    WO2022254362A1
点击查看最新优质反应信息

文献信息

  • NOVEL HETEROCYCLYL COMPOUNDS
    申请人:Aebi Johannes
    公开号:US20110092698A1
    公开(公告)日:2011-04-21
    The invention is concerned with novel bicyclic compounds of formula (I), wherein n, m, p, A, L, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 7 , R 8 , R 9 , and R 10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor may be used, for example, in the prevention and/or treatment of inflammatory diseases, particularly peripheral arterial occlusive diseases or atherothrombosis.
    这项发明涉及式(I)的新颖双环化合物,其中n、m、p、A、L、R1、R2、R3、R4、R5、R6、R7、R7、R8、R9和R10如描述和索赔中所定义,并且其生理上可接受的盐。这些化合物是CCR2受体、CCR5受体和/或CCR3受体的拮抗剂,例如可用于预防和/或治疗炎症性疾病,特别是外周动脉闭塞疾病或动脉粥样硬化形成。
  • SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS
    申请人:Bignan Gilles
    公开号:US20110294780A1
    公开(公告)日:2011-12-01
    The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
    本发明涉及式(I)的化合物,制备这些化合物的方法,组合物,中间体及其衍生物,并用于治疗包括但不限于强直性脊柱炎,动脉粥样硬化,关节炎(如类风湿关节炎,感染性关节炎,儿童关节炎,银屑病性关节炎,反应性关节炎),与骨相关的疾病(包括与骨形成有关的疾病),乳腺癌(包括对抗雌激素治疗无效的癌症),心血管疾病,软骨相关疾病(如软骨损伤/丧失,软骨退化以及与软骨形成有关的疾病),软骨发育不良,软骨肉瘤,慢性腰部损伤,慢性支气管炎,慢性炎症性气道疾病,慢性阻塞性肺疾病,糖尿病,能量稳态紊乱,痛风,假性痛风,脂质紊乱,代谢综合征,多发性骨髓瘤,肥胖,骨关节炎,遗传性骨发育不全,骨溶解性骨转移,软骨软化症,骨质疏松症,帕金森病,牙周病,多肌痛风,Reiter综合征,重复性应激损伤,高血糖,血糖水平升高和胰岛素抵抗等病症的方法。
  • Oxy-fluoropiperidine Derivative as Kinase Inhibitor
    申请人:Daewoong Pharmaceutical Co., Ltd.
    公开号:US20200308177A1
    公开(公告)日:2020-10-01
    The present invention relates to a compound represented by the following Chemical Formula 1, or a pharmaceutically acceptable salt thereof, and the compound according to the present invention can be usefully used for the prevention or treatm ent of diseases which are associated with kinase inhibitory actions.
    本发明涉及以下化学式1所表示的化合物或其药学上可接受的盐,而根据本发明的化合物可以用于预防或治疗与激酶抑制作用相关的疾病。
  • PYRROLOPYRIDINES AS KINASE INHIBITORS
    申请人:Le Huerou Yvan
    公开号:US20110070317A1
    公开(公告)日:2011-03-24
    Compounds of Formula (I) are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    化学式(I)的化合物对于抑制CHK1和/或CHK2非常有用。本文揭示了使用化学式(I)的化合物及其立体异构体和药学上可接受的盐,在哺乳动物细胞中进行体外、体内和原位诊断、预防或治疗此类疾病或相关病理状态的方法。
  • Pyrrolopyridines as kinase inhibitors
    申请人:Array BioPharma Inc.
    公开号:US08178131B2
    公开(公告)日:2012-05-15
    Compounds of Formula (I) are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    式(I)的化合物可用于抑制CHK1和/或CHK2。本文揭示了使用式(I)的化合物及其立体异构体和药学上可接受的盐,在哺乳动物细胞中进行体外,体内和原位诊断,预防或治疗此类疾病或相关病理条件的方法。
查看更多